Matthew Bohm, DO
Indiana University Hospital
Indianapolis, IN

Dr. Matthew Bohm is board certified in internal medicine and gastroenterology. His clinical interests include the diagnosis and management of inflammatory bowel disease, microscopic colitis, gastrointestinal bleeding, Clostridium difficile colitis, colon cancer screening, celiac disease and small intestinal bacteria overgrowth. His research interests include biomarkers of disease activity and severity in Crohn's disease and ulcerative colitis, and fecal transplantation.

 A Registry for all Patients Undergoing Small Bowel Enteroscopy with Fluid Aspiration and Culture for Evaluation for Small Intestinal Bacterial Overgrowth. Principal Investigator

 A Pilot Study to Evaluate if Response to Infliximab or Adalimumab may be regained with the Addition of an Immunomodulator. Principal Investigator

 Vedolizumab retrospective analysis trial: Victory Consortium is comprised of 15 leading academic centers in inflammatory bowel disease in North America evaluating the real world experience with Vedolizumab. Principal Investigator.

 Muli-Center Retrospective Trial Evaluating Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease on Biologic Medications. Collaborating with seven academic centers in the United States. Principal Investigator.

 Multi-center Analysis of Patients with Crohn’s Disease on Ustekinumab: Principal Investigator

 Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients with Crohn’s Disease. (Multiple center study funded by the Crohn’s Colitis Foundation of America) Subinvestigator

 Fecal Microbiota Transplantation Database (Largest fecal transplant database in United States) Subinvestigator

 The ICON Study: Inflammatory Bowel Disease and Recurrent Clostridium difficile Infection: Outcomes after Fecal Microbiota Transplantation (Multiple center study funded by the Crohn’s Colitis Foundation of America) Subinvestigator

 Opioid Prescription Trends in Patients with Inflammatory Bowel Disease During the National Opioid Crisis Principal Investigator

 Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease (Gilead): Principal Investigator.

 A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD) (Gilead): Principal Investigator

 A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease. (Gilead): Principal Investigator

 A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease. (Gilead): Principal Investigator

 A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha Therapy (Allergan) Subinvestigator.

 A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects with Active Crohn’s Disease (SERENITY) (Lilly) Subinvestigator

 ONWARD is an Observational, Real-World Study of InflectRa in patients with IBD (Pfizer). Subinvestigator

 Safety of fecal microbiota Transplantation: Openbiome Outcomes and Longitudinal follow-up (STOOL) for recurrent Clostridium difficileinfection. (Openbiome) Subinvestigator

 A Randomized Controlled Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization. (Openbiome) Subinvestigator

 A Cohort Dose-Escalation Study to Evaluate the Safety of Metrodora Therapeutics' Bovine Lactoferrin (MTbLF) in Patients with Anemia in Crohn's Disease. Subinvestigator

 DINE Study An Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients with Crohn’s Disease Subinvestigator

    Webcasts

    Impact of IBD on Healthcare Systems

    Gary Lichtenstein, MD ; David Rubin, MD ; Bruce Sands, MD ; Brennan Spiegel, MD ; Douglas Wolf, MD

    Didactic Lecture

    view details >

    eMonograph

    Clinical and Managed Care Perspectives in Inflammatory Bowel Disease: Closing the Gap

    view details >

    Addressing Health Outcomes and Rising Costs in the Management of Inflammatory Bowel Disease

    view details >

    The Guide to Guidelines in IBD: Interpretation and Appropriate Use in Clinical Practice

    view details >

    INFORM UC: An Update on Contemporary Management of UC

    view details >

    Breaking The Barriers: Improving Access to Biologic Therapies in IBD

    view details >

    IBD Management: State of the Art in 2018

    view details >

    Improving IBD Care A Personalized Approach to Management

    view details >

    Expert Perspectives in the Management of Inflammatory Bowel Disease (IBD): A Review of Recent Advances

    view details >

    Advances in IBD

    view details >

    Optimizing the Management of Inflammatory Bowel Disease

    view details >

    Webcasts

    Impact of IBD on Healthcare Systems

    Gary Lichtenstein, MD ; David Rubin, MD ; Bruce Sands, MD ; Brennan Spiegel, MD ; Douglas Wolf, MD

    Didactic Lecture

    view details >

    Dinner Meetings

    Content available soon

    Audiocasts

    Content available soon!

    Content available soon!

    © Copyright 2013-2024 GI Health Foundation. All rights reserved.
    This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.